We found significantly higher OR scores for DCIS lesions with a HER2+ molecular subtype (OR = 16.49; 95% CI, 3.62–75.14), ER negativity (OR = 11.55; 95% CI, 2.50–53.48), PR negativity (OR = 2.67; 95% CI, 1.22–5.84), Ki67 ≥ 20% (OR = 8.41; 95% CI, 2.89–24.46), ER-low DCIS subtype (OR = 8.31; 95% Cl, 1.60–41.36), solid growth (OR = 6.76; 95% CI, 2.85–16.04), comedonecrosis (OR = 2.85; 95% CI, 1.21–6.74), or grade 3 (OR = 2.95; 95% CI, 1.37–6.38). This evidence concerns the gene MKI67 and ductal breast carcinoma in situ.